Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | PI4KA | P42356 | 6/20 | 0.37 |
| ▸ | PI4K2B | Q8TCG2 | 6/20 | 0.37 |
| ▸ | PI4K2A | Q9BTU6 | 6/20 | 0.37 |
| ▸ | PI4KB | Q9UBF8 | 6/20 | 0.37 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 2/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6016628 | 0.81 | CHEK1 (0.37) | ADORA2AADORA1 | |
| SCHEMBL42313 | 0.78 | ADORA2A (0.42) | ADORA2AADORA1ERAP1MAP4K4LMNA | |
| SCHEMBL4572191 | 0.78 | CCNB2 (0.38) | — | |
| SCHEMBL160304 | 0.75 | ADORA2A (0.40) | ADORA2AADORA1ERAP1MAP4K4LMNA | |
| SCHEMBL12620888 | 0.75 | ADORA2A (0.40) | ADORA2AADORA1ERAP1MAP4K4LMNA | |
| SCHEMBL4581404 | 0.75 | PI4KA (0.41) | ADORA2AADORA1ERAP1LMNAPI4KA | |
| SCHEMBL953009 | 0.75 | NUDT1 (0.41) | ADORA2AADORA1ERAP1MAP4K4PI4KA | |
| SCHEMBL159639 | 0.75 | ADORA2A (0.40) | ADORA2AADORA1ERAP1MAP4K4LMNA | |
| SCHEMBL8565 | 0.75 | ADORA2A (0.58) | ADORA2AADORA1ERAP1LMNAPI4KA | |
| SCHEMBL42336 | 0.75 | PIK3CG (0.42) | ADORA2AADORA1ERAP1LMNAPI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 241 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122029176-A | Containing a plurality of oligonucleotides modified oligonucleotides | 阿达尔克斯制药有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-122029177-A | Oligonucleotides containing multiple ligands and/or lipids | 阿达尔克斯制药有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-122028913-A | Oligonucleotides containing ligands in nucleobases, 2 'or 3' positions | 阿达尔克斯制药有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-20250257360-A1 | OLIGONUCLEOTIDE INTERFERENCE TREATMENTS OF PROSTATE CANCER | UNIV OKLAHOMA (US) | 2025-08-14 | — | — | US | claimed |
| CN-113151261-B | Antisense oligonucleotides as inhibitors of TGF-R signaling | 神经视觉医药有限公司 | 2025-06-17 | — | — | CN | claimed |
| WO-2025111430-A1 | CHEMICAL MODIFICATIONS IN mRNA POLY(A) TAIL | PRIME MEDICINE, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| WO-2025111452-A2 | CHEMICAL MODIFICATIONS IN PEgRNA and ngRNAs | PRIME MEDICINE, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| WO-2025043082-A2 | COMPOSITIONS AND METHODS TO IMPROVE RNA PROPERTIES USING BASE, PHOSPHODIESTER LINKAGE, SUGAR BACKBONE, AND CAP MODIFICATIONS | THE BROAD INSTITUTE, INC. (US) | 2025-02-27 | — | — | WO | claimed |
| WO-2025038970-A1 | MODIFIED OLIGONUCLEOTIDES CONTAINING MULTIPLE OLIGONUCLEOTIDES | ADARX PHARMACEUTICALS, INC. (US) | 2025-02-20 | — | — | WO | claimed |
| WO-2025038963-A1 | OLIGONUCLEOTIDES CONTAINING MULTIPLE LIGANDS AND/OR LIPIDS | ADARX PHARMACEUTICALS, INC. (US) | 2025-02-20 | — | — | WO | claimed |
| US-20170319614-A1 | ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING | Neurovision Pharma GmbH (DE) | 2017-11-09 | — | — | US | claimed |
| EP-3218488-A1 | ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING | Neurovision Pharma GmbH (DE) | 2017-09-20 | — | — | EP | claimed |
| CN-107002082-A | Antisense oligonucleotides as inhibitors of TGF-R signaling | 神经视觉医药有限公司 | 2017-08-01 | — | — | CN | claimed |
| WO-2016075339-A1 | ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING | Neurovision Pharma GmbH (DE) | 2016-05-19 | — | — | WO | claimed |
| US-20160138029-A1 | ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING | Neurovision Pharma GmbH (DE) | 2016-05-19 | — | — | US | claimed |
| EP-0898575-B1 | A COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | KOESTER HUBERT DR (US) | 2004-12-29 | — | — | EP | claimed |
| US-20030194741-A1 | COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | CAPROTEC BIOANALYTICS GMBH (DE) | 2003-10-16 | — | — | US | claimed |
| US-20030054410-A1 | Combinatorial protecting group strategy for multifunctional molecules | CAPROTEC BIOANALYTICS GMBH (DE) | 2003-03-20 | — | — | US | claimed |
| EP-0898575-A2 | A COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | KÖSTER, Hubert (US) | 1999-03-03 | — | — | EP | claimed |
| WO-1997041139-A2 | A COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | KOESTER HUBERT (US) | 1997-11-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030194741-A1 | COMBINATORIAL PROTECTING GROUP STRATEGY FOR MULTIFUNCTIONAL MOLECULES | ADAR, RNMT, ATIC | ADORA2A 113/4885ADORA1 242/4885ERAP1 1566/4885 |
| US-20170319614-A1 | ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING | TGFBR1, TGFBR2, TGFB1 | ADORA2A 1258/4885ADORA1 689/4885ERAP1 1120/4885 |
| US-20030054410-A1 | Combinatorial protecting group strategy for multifunctional molecules | ADAR, RNMT, RRM1 | ADORA2A 123/4885ADORA1 217/4885ERAP1 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.